Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry

Nature Communications

Volumn 7, Issue , 2016, Pages

  Bassani Sternberg, Michal ^a,e   Bräunlein, Eva ^b   Klar, Richard ^b   Engleitner, Thomas ^b,c   Sinitcyn, Pavel ^a   Audehm, Stefan ^b   Straub, Melanie ^d   Weber, Julia ^b,c   Slotta Huspenina, Julia ^d   Specht, Katja ^d   Martignoni, Marc E ^b   Werner, Angelika ^b   Hein, Rüdiger ^b   Busch, Dirk H ^d   Peschel, Christian ^b,c   Rad, Roland ^b,c   Cox, Jürgen ^a   Mann, Matthias ^a   Krackhardt, Angela M ^b,c  

^a MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e LUDWIG INSTITUTE FOR CANCER RESEARCH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; CANCER TESTIS ANTIGEN; COMPLEMENTARY DNA; CYTOKINE; GAMMA INTERFERON; GENOMIC DNA; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; IPILIMUMAB; PEPTIDE; PHOSPHOPEPTIDE; PROGRAMMED DEATH 1 LIGAND 1; TUMOR ANTIGEN; EPITOPE; LIGAND;

ANTIGEN; CANCER; CELLS AND CELL COMPONENTS; IDENTIFICATION METHOD; IMMUNE RESPONSE; LIGAND; MASS SPECTROMETRY; MUTATION; PEPTIDE; TUMOR;

ARTICLE; BLOOD; CYTOKINE RELEASE; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MELANOMA; METASTASIS RESECTION; PROTEIN PHOSPHORYLATION; SOMATIC MUTATION; T LYMPHOCYTE; TANDEM MASS SPECTROMETRY; ANTIGEN PRESENTATION; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; MOLECULAR CLONING; MUTATION; NUCLEOTIDE SEQUENCE;

ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; BASE SEQUENCE; CLONING, MOLECULAR; EPITOPES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIGANDS; MASS SPECTROMETRY; MELANOMA; MUTATION; PEPTIDES;

EID: 84995916390     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms13404     Document Type: Article

References (64)

1. Page, D. B., Postow, M. A., Callahan, M. K., Allison, J. P. & Wolchok, J. D. Immune modulation in cancer with antibodies. Ann. Rev. Med. 65, 185-202 (2014).
2. Weber, J. S. et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 16, 375-384 (2015).
3. van Baren, N. et al. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 23, 9008-9021 (2005).
4. Schwartzentruber, D. J. et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N. Engl. J. Med. 364, 2119-2127 (2011).
5. Robbins, P. F. et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 29, 917-924 (2011).
6. Morgan, R. A. et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126-129 (2006).
7. Johnson, L. A. et al. Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. J. Immunol. 177, 6548-6559 (2006).
8. Linette, G. P. et al. Cardiovascular toxicity and titin cross-reactivity of affinityenhanced T cells in myeloma and melanoma. Blood 122, 863-871 (2013).
9. Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010).
10. Larkin, J. et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N. Engl. J. Med. 373, 23-34 (2015).
11. Robert, C. et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N. Engl. J. Med. 372, 2521-2532 (2015).
12. Rizvi, N. A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124-128 (2015).
13. Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189-2199 (2014).
14. Van Allen, E. M. et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207-211 (2015).
15. Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013).
16. Linnemann, C. et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat. Med. 21, 81-85 (2015).
17. van Rooij, N. et al. Tumor exome analysis reveals neoantigen-specific T-Cell reactivity in an ipilimumab-responsive melanoma. J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 31, e439-e442 (2013).
18. Kreiter, S. et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 520, 692-696 (2015).
19. Tran, E. et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science 350, 1387-1390 (2015).
20. Lennerz, V. et al. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc. Natl Acad. Sci. USA 102, 16013-16018 (2005).
21. Yadav, M. et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 515, 572-576 (2014).
22. Gubin, M. M. et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515, 577-581 (2014).
23. Kalaora, S. et al. Use of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigens. Oncotarget 7, 5110-5117 (2016).
24. McGranahan, N. et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351, 1463-1469 (2016).
25. Bassani-Sternberg, M., Pletscher-Frankild, S., Jensen, L. J. & Mann, M. Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation. Mol. Cell. Proteom.: MCP 14, 658-673 (2015).
26. Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 26, 1367-1372 (2008).
27. Andreatta, M., Lund, O. & Nielsen, M. Simultaneous alignment and clustering of peptide data using a Gibbs sampling approach. Bioinformatics 29, 8-14 (2013).
28. Caron, E. et al. Analysis of Major Histocompatibility Complex (MHC) Immunopeptidomes Using Mass Spectrometry. Mol. Cell. Proteom.: MCP 14, 3105-3117 (2015).
29. Hoof, I. et al. NetMHCpan, a method for MHC class I binding prediction beyond humans. Immunogenetics 61, 1-13 (2009).
30. Hornbeck, P. V. et al. PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. Nucleic Acids Res. 43, D512-D520 (2015).
31. Mohammed, F. et al. Phosphorylation-dependent interaction between antigenic peptides and MHC class I: a molecular basis for the presentation of transformed self. Nat. Immunol. 9, 1236-1243 (2008).
32. Cobbold, M. et al. MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia. Sci. Transl. Med. 5, 203ra125 (2013).
33. Schittenhelm, R. B., Dudek, N. L., Croft, N. P., Ramarathinam, S. H. & Purcell, A. W. A comprehensive analysis of constitutive naturally processed and presented HLA-C∗04:01 (Cw4)-specific peptides. Tissue Antigens 83, 174-179 (2014).
34. Trolle, T. et al. The length distribution of class I-restricted T cell epitopes is determined by both peptide supply and mhc allele-specific binding preference. J. Immunol. 196, 1480-1487 (2016).
35. McMurtrey, C. et al. Toxoplasma gondii peptide ligands open the gate of the HLA class I binding groove. Elife 5, e12556 (2016).
36. Apcher, S., Prado Martins, R. & Fahraeus, R. The source of MHC class I presented peptides and its implications. Curr. Opin. Immunol. 40, 117-122 (2016).
37. Rodriguez, A., Regnault, A., Kleijmeer, M., Ricciardi-Castagnoli, P. & Amigorena, S. Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat. Cell Biol. 1, 362-368 (1999).
38. Abelin, J. G. et al. Complementary IMAC enrichment methods for HLAassociated phosphopeptide identification by mass spectrometry. Nat. Protoc. 10, 1308-1318 (2015).
39. Sharma, K. et al. Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep. 8, 1583-1594 (2014).
40. Lu, K. P., Liou, Y. C. & Zhou, X. Z. Pinning down proline-directed phosphorylation signaling. Trends Cell Biol. 12, 164-172 (2002).
41. Zarling, A. L. et al. MHC-restricted phosphopeptides from insulin receptor substrate-2 and CDC25b offer broad-based immunotherapeutic agents for cancer. Cancer Res. 74, 6784-6795 (2014).
42. Verdegaal, E. M. et al. Neoantigen landscape dynamics during human melanoma-T cell interactions. Nature 536, 91-95 (2016).
43. Stronen, E. et al. Targeting of cancer neoantigens with donor-derived T cell receptor repertoires. Science 352, 1337-1341 (2016).
44. Gros, A. et al. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat. Med. 22, 433-438 (2016).
45. Chambers, C. A., Kuhns, M. S. & Allison, J. P. Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates primary and secondary peptide-specific CD4(+) T cell responses. Proc. Natl Acad. Sci. USA 96, 8603-8608 (1999).
46. Cohen, C. J. et al. Isolation of neoantigen-specific T cells from tumour and peripheral lymphocytes. J. Clin. Investig. 125, 3981-3991 (2015).
47. Lu, Y. C. et al. Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumour regressions. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 20, 3401-3410 (2014).
48. Jenkins, M. R. et al. Visualizing CTL activity for different CD8+ effector T cells supports the idea that lower TCR/epitope avidity may be advantageous for target cell killing. Cell Death Differ. 16, 537-542 (2009).
49. Klar, R. et al. Therapeutic targeting of naturally presented myeloperoxidasederived HLA peptide ligands on myeloid leukemia cells by TCR-transgenic T cells. Leukemia 28, 2355-2366 (2014).
50. Cox, J. et al. Andromeda: a peptide search engine integrated into the MaxQuant environment. J. Proteome Res. 10, 1794-1805 (2011).
51. Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213-219 (2013).
52. Schmieder, R. & Edwards, R. Quality control and preprocessing of metagenomic datasets. Bioinformatics 27, 863-864 (2011).
53. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754-1760 (2009).
54. McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297-1303 (2010).
55. Cingolani, P. et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin) 6, 80-92 (2012).
56. Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402-408 (2001).
57. Warren, R. L. et al. Derivation of HLA types from shotgun sequence datasets. Genome Med. 4, 95 (2012).
58. Andreatta, M. & Nielsen, M. Gapped sequence alignment using artificial neural networks: application to the MHC class I system. Bioinformatics 32, 511-517 (2015).
59. Karosiene, E., Lundegaard, C., Lund, O. & Nielsen, M. NetMHCcons: a consensus method for the major histocompatibility complex class I predictions. Immunogenetics 64, 177-186 (2012).
60. Weigand, L. U. et al. Isolation of human MHC class II-restricted T cell receptors from the autologous T-cell repertoire with potent anti-leukaemic reactivity. Immunology 137, 226-238 (2012).
61. Martinuzzi, E. et al. acDCs enhance human antigen-specific T-cell responses. Blood 118, 2128-2137 (2011).
62. Knabel, M. et al. Reversible MHC multimer staining for functional isolation of T-cell populations and effective adoptive transfer. Nat. Med. 8, 631-637 (2002).
63. Wang, R. F. Molecular cloning and characterization of MHC class I-and II-restricted tumor antigens recognized by T cells. Curr. Protoc 84, 20.10.1-20.10.29 (2009).
64. Vizcaino, J. A. et al. ProteomeXchange provides globally coordinated proteomics data submission and dissemination. Nat. Biotechnol. 32, 223-226 (2014).